Evidence map›Paper›PMID 38712261›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States Nationwide Prospective Cohort Study.

Eryka Wentz, Zhanmo Ni, Karine Yenokyan, Candelaria Vergara, Jessica Pahwa, Thea Kammerling, Pu Xiao, Priya Duggal, Bryan Lau, Shruti H Mehta

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Eryka WentzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Zhanmo NiDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD.
Karine YenokyanDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Candelaria VergaraDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Jessica PahwaTemple University Kornberg School of Dentistry, Philadelphia, PA.
Thea KammerlingDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Pu XiaoDepartment of Applied Mathematics and Statistics, Johns Hopkins Whiting School of Engineering, Baltimore, MD.
Priya DuggalDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.ORCID 0000-0001-5809-2081
Bryan LauDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Shruti H MehtaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
NIAID NIH HHS P30 AI094189
6 · The paper itself

Abstract

Purpose: COVID-19 disease continues to affect millions of individuals worldwide, both in the short and long term. The post-acute complications of SARS-CoV-2 infection, referred to as long COVID, result in diverse symptoms affecting multiple organ systems. Little is known regarding how the symptoms associated with long COVID progress and resolve over time. The Johns Hopkins COVID Long Study aims to prospectively examine the short- and long-term consequences of COVID-19 disease in individuals both with and without a history of SARS-CoV-2 infection using self-reported data collected in an online survey. Participants: Sixteen thousand, seven hundred sixty-four adults with a history of SARS-CoV-2 infection and 799 adults without a history of SARS-CoV-2 infection who completed an online baseline survey. Findings to date: This cohort profile describes the baseline characteristics of the Johns Hopkins COVID Long Study. Among 16,764 participants with a history of SARS-CoV-2 infection and defined long COVID status, 75% reported a good or excellent health status prior to infection, 99% reported experiencing at least one COVID-19 symptom during the acute phase of infection, 9.9% reported a hospitalization, and 63% were defined as having long COVID using the WHO definition. Future plans: Analysis of longitudinal data will be used to investigate the progression and resolution of long COVID symptoms over time.

Indexed as

Chronic DiseaseCOVID-19Epidemiologic StudiesInfectious DiseasesSARS-CoV-2

Identifiers

PMID38712261
PMCPMC11071583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.